Search results
Results from the WOW.Com Content Network
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), [a] is a type of chronic liver disease. This condition is diagnosed when there is excessive fat build-up in the liver ( hepatic steatosis ), and at least one metabolic risk factor.
An animal model (short for animal disease model) is a living, non-human, often genetic-engineered animal used during the research and investigation of human disease, for the purpose of better understanding the disease process without the risk of harming a human. Although biological activity in an animal model does not ensure an effect in humans ...
The Andersen healthcare utilization model is a conceptual model aimed at demonstrating the factors that lead to the use of health services. According to the model, the usage of health services (including inpatient care, physician visits, dental care etc.) is determined by three dynamics: predisposing factors, enabling factors, and need.
In spite of the efforts in developing this mouse model, poor engraftment of human hematopoietic stem cells (HSCs) was a major limitation that called for further advancement in the development humanized mouse models. [5] Nude mice were the earliest immunodeficient mouse model. These mice primarily produced IgM and had minimal or no IgA.
Liver diseases, including conditions such as non-alcoholic fatty liver disease (NAFLD), alcohol-related liver disease (ALD), and viral hepatitis, are significant public health concerns worldwide. In the United States, NAFLD is the most common chronic liver condition, affecting approximately 24% of the population, with the prevalence rising due ...
Non-obese diabetic or NOD mice, like biobreeding rats, are used as an animal model for type 1 diabetes. [1] Diabetes develops in NOD mice as a result of insulitis, a leukocytic infiltrate of the pancreatic islets. [2] The onset of diabetes is associated with a moderate glycosuria and a non-fasting hyperglycemia.
Treatment of EET analog is beneficial for hepatic insulin signaling in mouse model of insulin resistance. [47] These interventions also gave beneficial results in animal models of non-alcoholic fatty liver disease and certain types inflammation-related kidney diseases including chronic kidney disease, renal ischemia-reperfusion injury, and ...
GLP-1 agonists are being studied for the treatment of non-alcoholic fatty liver disease (NAFLD). They are at least as effective as the medications in current use, pioglitazone and Vitamin E , and significantly reduce steatosis, ballooning necrosis, lobular inflammation, and fibrosis according to a 2023 systematic review. [ 18 ]